A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein.
Anti-angiogenic therapies are effective for the treatment of cancer, a variety of ocular diseases, and have potential benefits in cardiovascular disease, arthritis, and psoriasis. We have previously shown that anthrax protective antigen (PA), a non-pathogenic component of anthrax toxin, is an inhibi...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3386954?pdf=render |
id |
doaj-55c5e1601b864d598297d7ee12903fa7 |
---|---|
record_format |
Article |
spelling |
doaj-55c5e1601b864d598297d7ee12903fa72020-11-25T02:32:13ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0176e3991110.1371/journal.pone.0039911A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein.Michael S RogersLorna M CryanKaiane A HabeshianLauren BazinetThomas P CaldwellP Christine AckroydKenneth A ChristensenAnti-angiogenic therapies are effective for the treatment of cancer, a variety of ocular diseases, and have potential benefits in cardiovascular disease, arthritis, and psoriasis. We have previously shown that anthrax protective antigen (PA), a non-pathogenic component of anthrax toxin, is an inhibitor of angiogenesis, apparently as a result of interaction with the cell surface receptors capillary morphogenesis gene 2 (CMG2) protein and tumor endothelial marker 8 (TEM8). Hence, molecules that bind the anthrax toxin receptors may be effective to slow or halt pathological vascular growth. Here we describe development and testing of an effective homogeneous steady-state fluorescence resonance energy transfer (FRET) high throughput screening assay designed to identify molecules that inhibit binding of PA to CMG2. Molecules identified in the screen can serve as potential lead compounds for the development of anti-angiogenic and anti-anthrax therapies. The assay to screen for inhibitors of this protein-protein interaction is sensitive and robust, with observed Z' values as high as 0.92. Preliminary screens conducted with a library of known bioactive compounds identified tannic acid and cisplatin as inhibitors of the PA-CMG2 interaction. We have confirmed that tannic acid both binds CMG2 and has anti-endothelial properties. In contrast, cisplatin appears to inhibit PA-CMG2 interaction by binding both PA and CMG2, and observed cisplatin anti-angiogenic effects are not mediated by interaction with CMG2. This work represents the first reported high throughput screening assay targeting CMG2 to identify possible inhibitors of both angiogenesis and anthrax intoxication.http://europepmc.org/articles/PMC3386954?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Michael S Rogers Lorna M Cryan Kaiane A Habeshian Lauren Bazinet Thomas P Caldwell P Christine Ackroyd Kenneth A Christensen |
spellingShingle |
Michael S Rogers Lorna M Cryan Kaiane A Habeshian Lauren Bazinet Thomas P Caldwell P Christine Ackroyd Kenneth A Christensen A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein. PLoS ONE |
author_facet |
Michael S Rogers Lorna M Cryan Kaiane A Habeshian Lauren Bazinet Thomas P Caldwell P Christine Ackroyd Kenneth A Christensen |
author_sort |
Michael S Rogers |
title |
A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein. |
title_short |
A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein. |
title_full |
A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein. |
title_fullStr |
A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein. |
title_full_unstemmed |
A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein. |
title_sort |
fret-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2012-01-01 |
description |
Anti-angiogenic therapies are effective for the treatment of cancer, a variety of ocular diseases, and have potential benefits in cardiovascular disease, arthritis, and psoriasis. We have previously shown that anthrax protective antigen (PA), a non-pathogenic component of anthrax toxin, is an inhibitor of angiogenesis, apparently as a result of interaction with the cell surface receptors capillary morphogenesis gene 2 (CMG2) protein and tumor endothelial marker 8 (TEM8). Hence, molecules that bind the anthrax toxin receptors may be effective to slow or halt pathological vascular growth. Here we describe development and testing of an effective homogeneous steady-state fluorescence resonance energy transfer (FRET) high throughput screening assay designed to identify molecules that inhibit binding of PA to CMG2. Molecules identified in the screen can serve as potential lead compounds for the development of anti-angiogenic and anti-anthrax therapies. The assay to screen for inhibitors of this protein-protein interaction is sensitive and robust, with observed Z' values as high as 0.92. Preliminary screens conducted with a library of known bioactive compounds identified tannic acid and cisplatin as inhibitors of the PA-CMG2 interaction. We have confirmed that tannic acid both binds CMG2 and has anti-endothelial properties. In contrast, cisplatin appears to inhibit PA-CMG2 interaction by binding both PA and CMG2, and observed cisplatin anti-angiogenic effects are not mediated by interaction with CMG2. This work represents the first reported high throughput screening assay targeting CMG2 to identify possible inhibitors of both angiogenesis and anthrax intoxication. |
url |
http://europepmc.org/articles/PMC3386954?pdf=render |
work_keys_str_mv |
AT michaelsrogers afretbasedhighthroughputscreeningassaytoidentifyinhibitorsofanthraxprotectiveantigenbindingtocapillarymorphogenesisgene2protein AT lornamcryan afretbasedhighthroughputscreeningassaytoidentifyinhibitorsofanthraxprotectiveantigenbindingtocapillarymorphogenesisgene2protein AT kaianeahabeshian afretbasedhighthroughputscreeningassaytoidentifyinhibitorsofanthraxprotectiveantigenbindingtocapillarymorphogenesisgene2protein AT laurenbazinet afretbasedhighthroughputscreeningassaytoidentifyinhibitorsofanthraxprotectiveantigenbindingtocapillarymorphogenesisgene2protein AT thomaspcaldwell afretbasedhighthroughputscreeningassaytoidentifyinhibitorsofanthraxprotectiveantigenbindingtocapillarymorphogenesisgene2protein AT pchristineackroyd afretbasedhighthroughputscreeningassaytoidentifyinhibitorsofanthraxprotectiveantigenbindingtocapillarymorphogenesisgene2protein AT kennethachristensen afretbasedhighthroughputscreeningassaytoidentifyinhibitorsofanthraxprotectiveantigenbindingtocapillarymorphogenesisgene2protein AT michaelsrogers fretbasedhighthroughputscreeningassaytoidentifyinhibitorsofanthraxprotectiveantigenbindingtocapillarymorphogenesisgene2protein AT lornamcryan fretbasedhighthroughputscreeningassaytoidentifyinhibitorsofanthraxprotectiveantigenbindingtocapillarymorphogenesisgene2protein AT kaianeahabeshian fretbasedhighthroughputscreeningassaytoidentifyinhibitorsofanthraxprotectiveantigenbindingtocapillarymorphogenesisgene2protein AT laurenbazinet fretbasedhighthroughputscreeningassaytoidentifyinhibitorsofanthraxprotectiveantigenbindingtocapillarymorphogenesisgene2protein AT thomaspcaldwell fretbasedhighthroughputscreeningassaytoidentifyinhibitorsofanthraxprotectiveantigenbindingtocapillarymorphogenesisgene2protein AT pchristineackroyd fretbasedhighthroughputscreeningassaytoidentifyinhibitorsofanthraxprotectiveantigenbindingtocapillarymorphogenesisgene2protein AT kennethachristensen fretbasedhighthroughputscreeningassaytoidentifyinhibitorsofanthraxprotectiveantigenbindingtocapillarymorphogenesisgene2protein |
_version_ |
1724820605066280960 |